The DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.
Somatic mutations affect key pathways in lung adenocarcinoma
Open accessAbstract
Determining the genetic basis of cancer requires comprehensive analyses of large collections of histopathologically well-classified primary tumours. Here we report the results of a collaborative study to discover somatic mutations in 188 human lung adenocarcinomas. DNA sequencing of 623 genes with known or potential relationships to cancer revealed more than 1,000 somatic mutations across the samples. Our analysis identified 26 genes that are mutated at significantly high frequencies and thus are probably involved in carcinogenesis. The frequently mutated genes include tyrosine kinases, among them the EGFR homologue ERBB4; multiple ephrin receptor genes, notably EPHA3; vascular endothelial growth factor receptor KDR; and NTRK genes. These data provide evidence of somatic mutations in primary lung adenocarcinoma for several tumour suppressor genes involved in other cancers--including NF1, APC, RB1 and ATM--and for sequence changes in PTPRD as well as the frequently deleted gene LRP1B. The observed mutational profiles correlate with clinical features, smoking status and DNA repair defects. These results are reinforced by data integration including single nucleotide polymorphism array and gene expression array. Our findings shed further light on several important signalling pathways involved in lung adenocarcinoma, and suggest new molecular targets for treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“While gain of 7p and loss of 8p have been previously reported to occur specifically in EGFR mutated adenocarcinomas16, 17, gain of 16p was a novel association.”
From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“KRAS mutations predominate in NSCLCs, accounting for ~78% of all RAS mutations found in such tumours17. The activating missense KRAS mutations that occur in ~25% of NSCLCs19–23 are typically mutually exclusive with other clinically actionable driver mutations, such as those in EGFR, BRAF and ALK24.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [22]
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [60]
In the citing paper
“Activating mutations in KRAS are the most prevalent oncogenic driver event in both early-stage and metastatic LUAD, occurring in 25–32% of tumors34, 59, 60, 62, 67.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [60]
In the citing paper
“Similarly, mutations in ERBB4 were identified in cancer, particularly melanoma (Prickett et al., 2009), lung adenocarcinoma (Ding et al., 2008), and medulloblastoma (Gilbertson et al., 2001).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Ding et al., 2008
In the citing paper
“Gain/amplification of the mutant EGFR allele has previously been reported to frequently occur in LAC and is known to drive tumor progression17.”
From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Self-citationEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citationPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Cited by
Sorted by citations
Items 701–800 of 1,007
Kim, H., Jang, S. J., Chung, D. H., Yoo, S. B., Sun, P., Jin, Y. J., Nam, K. H., Paik, J.-H., & Chung, J.-H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076999 · Cited by 66
Kono, S. A., Marshall, M. E., Ware, K. E., & Heasley, L. E. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.05.001 · Cited by 65
Oncogenic driver mutations in lung cancer
Luo, S. Y., & Lam, D. C.-L. (2013) · Translational Respiratory Medicine · doi:10.1186/2213-0802-1-6 · Cited by 70
Giaginis, C., Tsoukalas, N., Bournakis, E., Alexandrou, P. T., Kavantzas, N., Patsouris, E., & Theocharis, S. E. (2014) · BMC Clinical Pathology · doi:10.1186/1472-6890-14-8 · Cited by 66
Oncogenic Activating Mutations Are Associated with Local Copy Gain
Modrek, B., Ge, L., Pandita, A., Lin, E., Mohan, S., Yue, P., Guerrero, S., Lin, W. M., Pham, T. Q., Modrusan, Z. D., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0532 · Cited by 65
Multi-centre prospective study on diagnosing subtypes of lung cancer by exhaled-breath analysis
Kort, S., Tiggeloven, M., Brusse-Keizer, M. G. J., Gerritsen, J. W., Schouwink, J. H., Citgez, E., de Jongh, F. H., Samii, S., van der Maten, J., van den Bogart, M., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.09.022 · Cited by 66
Watanabe, H., Francis, J. M., Woo, M. S., Etemad, B., Lin, W., Fries, D. F., Peng, S., Snyder, E. L., Tata, P. R., Izzo, F., et al. (2013) · Genes & Development · doi:10.1101/gad.203208.112 · Cited by 64
Self-citationBerge, E. M., & Doebele, R. C. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.006 · Cited by 65
Vaughan, C. A., Singh, S. K., Windle, B. E., Yeudall, W. A., Frum, R. A., Grossman, S. R., Deb, S., & Deb, S. (2012) · Genes & Cancer · doi:10.1177/1947601912462719 · Cited by 65
Defining Key Signaling Nodes and Therapeutic Biomarkers in NF1 -Mutant Cancers
Malone, C. F., Longo, J. F., Maertens, O., Raedt, T. D., Ingraham, R., & Cichowski, K. M. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0159 · Cited by 65
Joseph, T. P., Chanda, W., Padhiar, A. A., Batool, S., LiQun, S., Zhong, M., & Huang, M. (2017) · Integrative Cancer Therapies · doi:10.1177/1534735417736861 · Cited by 66
Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells
Dominici, C., Sgarioto, N., Yu, Z., Sesma-Sanz, L., Masson, J., Richard, S., & Raynal, N. J. ‐. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01037-1 · Cited by 66
Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy
Bouyahya, A., Allam, A. E., Aboulaghras, S., Bakrim, S., Menyiy, N. E., Alshahrani, M. M., Awadh, A. A. A., Benali, T., Lee, L., Omari, N. E., et al. (2022) · Cancers · doi:10.3390/cancers14225520 · Cited by 67
Unique microRNA‐profiles in EGFR ‐mutated lung adenocarcinomas
Bjaanæs, M. M., Halvorsen, A. R., Solberg, S. K., Jørgensen, L. H., Dragani, T. A., Galvan, A., Colombo, F., Anderlini, M., Pastorino, U., Kure, E. H., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28828 · Cited by 65
Xiong, D., Li, G., Li, K., Xu, Q., Pan, Z., Ding, F. H., Vedell, P. T., Liu, P., Cui, P., Hua, X., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs210 · Cited by 65
Relation between smoking history and gene expression profiles in lung adenocarcinomas
Staaf, J., Jönsson, G. B., Jönsson, M., Karlsson, A., Isaksson, S., Salomonsson, A., Pettersson, H. M., Soller, M., Ewers, S., Johansson, L., et al. (2012) · BMC Medical Genomics · doi:10.1186/1755-8794-5-22 · Cited by 65
Domain landscapes of somatic mutations in cancer
Nehrt, N. L., Peterson, T. A., Park, D., & Kann, M. G. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-s4-s9 · Cited by 65
Dunzendorfer-Matt, T., Mercado, E. L., Maly, K., McCormick, F. P., & Scheffzek, K. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607298113 · Cited by 63
Multitasking discoidin domain receptors are involved in several and specific hallmarks of cancer
Henriet, E., Sala, M., Hammoud, A. A., Tuariihionoa, A., Martino, J. S. D., Ros, M., & Saltel, F. (2018) · Cell Adhesion & Migration · doi:10.1080/19336918.2018.1465156 · Cited by 65
NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes
An, Ö., Pendino, V., D’Antonio, M., Ratti, E., Gentilini, M., & Ciccarelli, F. D. (2014) · Database · doi:10.1093/database/bau015 · Cited by 63
LRP1B: A Giant Lost in Cancer Translation
Príncipe, C., Sousa, I., Prazeres, H., Soares, P., & Lima, R. T. (2021) · Pharmaceuticals · doi:10.3390/ph14090836 · Cited by 64
The role of LKB1 in lung cancer
Sánchez‐Céspedes, M. (2011) · Familial Cancer · doi:10.1007/s10689-011-9443-0 · Cited by 66
Primary Urethral Clear-Cell Adenocarcinoma
Mehra, R., Vats, P., Sundaram, S. K., Udager, A. M., Roh, M. H., Alva, A. S., Pan, J., Lonigro, R. J., Siddiqui, J., Weizer, A. Z., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.11.023 · Cited by 64
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Xu, K., Park, D., Magis, A. T., Zhang, J., Zhou, W., Sica, G., Ramalingam, S. S., Curran, W. J., & Deng, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1012-4 · Cited by 71
Tvorogov, D., Sundvall, M., Kurppa, K. J., Hollmén, M., Repo, S., Johnson, M. S., & Elenius, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805438200 · Cited by 64
Lum, L., & Clevers, H. C. (2012) · Science · doi:10.1126/science.1228179 · Cited by 64
Vandenbroucke, I., Marck, H. G. V., Verhasselt, P., Thys, K., Mostmans, W., Dumont, S., Eygen, V. V., Coen, K., Tuefferd, M., & Aerssens, J. (2011) · BioTechniques · doi:10.2144/000113733 · Cited by 63
Age- and Sex-Specific Genomic Profiles in Non–Small Cell Lung Cancer
Mostertz, W. C. (2010) · JAMA · doi:10.1001/jama.2010.80 · Cited by 64
Hecht, S. S., & Szabo, E. M. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0371 · Cited by 70
Xu, C., Zhao, L., Yue, P., Fang, G., Tao, H., Owonikoko, T. K., Ramalingam, S. S., Khuri, F. R., & Sun, S. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.6.16397 · Cited by 65
The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival
William, W. N., Kim, J.-S., Liu, D. D., Solis, L. M., Behrens, C., Lee, J. J., Lippman, S. M., Kim, S., Hong, W. K., Wistuba, I. I., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr036 · Cited by 63
Self-citationSmg1 haploinsufficiency predisposes to tumor formation and inflammation
Roberts, T. L., Ho, U. Y., Luff, J., Lee, C. S., Apte, S. H., MacDonald, K. P. A., Raggat, L. J., Pettit, A. R., Morrow, C. A., Waters, M. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215696110 · Cited by 63
TiMEx: a waiting time model for mutually exclusive cancer alterations
Constantinescu, S., Szczurek, E., Mohammadi, P., Rahnenführer, J., & Beerenwinkel, N. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv400 · Cited by 63
NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer
Dischinger, P. S., Tovar, E. A., Essenburg, C. J., Madaj, Z., Gardner, E., Callaghan, M. E., Turner, A. N., Challa, A. K., Kempston, T., Eagleson, B., et al. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0080-8 · Cited by 63
Kim, S. M., Shin, S. C., Kim, E. E., Kim, S., Park, K., Oh, S. J., & Jang, M. (2018) · ACS Nano · doi:10.1021/acsnano.8b01670 · Cited by 63
Haga, Y., Sakamoto, Y., Kajiya, K., Kawai, H., Oka, M., Motoi, N., Shirasawa, M., Yotsukura, M., WATANABE, S.-I. I., Arai, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43732-y · Cited by 62
Peyser, N. D., Du, Y., Li, H., Lui, V. W. Y., Xiao, X., Chan, T. A.-T., & Grandis, J. R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135750 · Cited by 62
Analysis of different HER ‐2 mutations in breast cancer progression and drug resistance
Sun, Z., Shi, Y., Shen, Y., Cao, L., Zhang, W., & Guan, X. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12662 · Cited by 64
Genotype to phenotype: Analyzing the effects of inherited mutations in colorectal cancer families
Heinen, C. D. (2009) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2009.09.004 · Cited by 67
Saintigny, P., Peng, S., Zhang, L., Sen, B., Wistuba, I. I., Lippman, S. M., Girard, L., Minna, J. D., Heymach, J. V., & Johnson, F. M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0030 · Cited by 62
Self-citationAre we missing the target? Cancer stem cells and drug resistance in non-small cell lung cancer.
Gottschling, S., Schnabel, P. A., Herth, F. J. F., & Herpel, E. (2012) · PubMed · Cited by 61
Novel Mutations in Neuroendocrine Carcinoma of the Breast
Ang, D. C., Ballard, M., Beadling, C., Warrick, A., Schilling, A., O’Gara, R., Pukay, M., Neff, T. L., West, R. B., Corless, C. L., et al. (2014) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pdm.0b013e3182a40fd1 · Cited by 62
Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer
Wei, X., Gao, X., Zhang, X., Yang, J., Chen, Z., Wu, Y.-L. L. C., & Zhou, Q. H. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13419 · Cited by 62
KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
Gu, M., Xu, T., & Chang, P. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211006950 · Cited by 68
Bisphosphonates inactivate human EGFRs to exert antitumor actions
Yuen, T., Stachnik, A., Iqbal, J. Z., Sgobba, M., Gupta, Y. K., Lü, P., Colaianni, G., Ji, Y., Zhu, L.-L., Kim, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421410111 · Cited by 61
Yang, F., Tang, X., Riquelme, E. M., Behrens, C., Nilsson, M. B., Giri, U. P., Varella‐Garcia, M., Byers, L. A., Lin, H. Y., Wang, J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2614 · Cited by 61
Self-citationRole and Relevance of TrkB Mutations and Expression in Non–Small Cell Lung Cancer
Harada, T., Yatabe, Y., Takeshita, M., Koga, T., Yano, T., Wang, Y., & Giaccone, G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3034 · Cited by 61
The Drosophila Accessory Gland as a Model for Prostate Cancer and Other Pathologies
WILSON, C. G., Leiblich, A., Goberdhan, D. C. I., & Hamdy, F. C. (2016) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2016.06.001 · Cited by 60
Hu, L., Liang, S., Chen, H., Lv, T., Wu, J., Chen, D., Wu, M. C., Sun, S., Zhang, H., You, H., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617816114 · Cited by 62
Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer
Lei, H., & Deng, C. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.20792 · Cited by 61
The Discovery of Mutated Driver Pathways in Cancer: Models and Algorithms
Zhang, J., & Zhang, S. (2016) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2016.2640963 · Cited by 62
Wu, S., Wang, L., Guo, W., Liu, X., Liu, J., Wei, X., & Fang, B. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101417n · Cited by 60
HER2 as a target in invasive urothelial carcinoma
Joaquim Bellmunt, B., Werner, L. L., Bamias, A., Fay, A. P., Park, R. S., Riester, M., Selvarajah, S., Barletta, J. A., Berman, D. M., de Muga, S., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.432 · Cited by 61
NEDD9 promotes lung cancer metastasis through epithelial-mesenchymal transition
Jin, Y., Li, F., Zheng, C., Wang, Y., Fang, Z., Guo, C., Wang, X., Liu, H., Deng, L., Li, C., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28568 · Cited by 62
Fiala, O., Pešek, M., Fínek, J., Benešová, L., Belšánová, B., & Minárik, M. (2013) · Cancer Genetics · doi:10.1016/j.cancergen.2012.12.003 · Cited by 61
Hai, J., Zhu, C., Bandarchi, B., Wang, Y., Navab, R., Shepherd, F. A., Jurišica, I., & Tsao, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2893 · Cited by 60
Sebastian, N., Xu‐Welliver, M., & Williams, T. M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.04.52 · Cited by 63
Zito, C. R., Jilaveanu, L. B., Anagnostou, V., Rimm, D. L., Bepler, G., Maira, S.-M., Hackl, W., Camp, R. L., Kluger, H. M., & Chao, H. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031331 · Cited by 60
Chong, S. Y., Cutler, S., Lin, J., Tsai, C.-H., Tsai, H., Biggins, S., Tsukiyama, T., Lo, Y., & Kao, C.-F. (2020) · Nature Communications · doi:10.1038/s41467-020-14595-4 · Cited by 60
Role of ancillary studies in fine‐needle aspiration from selected tumors
Schmitt, F. C., & Barroca, H. (2011) · Cancer Cytopathology · doi:10.1002/cncy.20197 · Cited by 59
Sacco, J. J., Kenyani, J., Butt, Z., Carter, R., Chew, H. Y., Cheeseman, L. P., Darling, S., Denny, M., Urbé, S., Clague, M. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3765 · Cited by 63
Androgen Receptor-Target Genes in African American Prostate Cancer Disparities
Wang, B., Yang, Q., Ceniccola, K., Bianco, F. J., Andrawis, R. I., Jarrett, T. W., Frazier, H. A., Patierno, S. R., & Lee, N. H. (2013) · Prostate Cancer · doi:10.1155/2013/763569 · Cited by 58
Li, J., Milbury, C. A., Li, C., & Makrigiorgos, G. M. (2009) · Human Mutation · doi:10.1002/humu.21112 · Cited by 58
Functional Characterization of Human Cancer-Derived TRKB Mutations
Geiger, T. R., Song, J., Rosado, A., & Peeper, D. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016871 · Cited by 58
Beauchamp, E. M., Woods, B. A., Dulak, A. M., Tan, L., Xu, C., Gray, N. S., Bass, A. J., Wong, K., Meyerson, M. M., & Hammerman, P. S. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0817 · Cited by 60
Self-citationKono, S. A., Heasley, L. E., Doebele, R. C., & Camidge, D. R. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912799095144 · Cited by 59
Detection of Impaired Homologous Recombination Repair in NSCLC Cells and Tissues
Birkelbach, M. A., Ferraiolo, N., Gheorghiu, L., Pfäffle, H. N., Daly, B. D. T., Ebright, M. I., Spencer, C., O’Hara, C., Whetstine, J. R., Benes, C. H., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827ecf83 · Cited by 59
Wang, L., Cao, L., Wen, C., Li, J., Yu, G., & Liu, C. (2019) · Human Cell · doi:10.1007/s13577-019-00296-8 · Cited by 59
Comprehensive assessment of computational algorithms in predicting cancer driver mutations
Chen, H., Li, J., Wang, Y., Ng, P. K., Tsang, Y. H., Shaw, K. R. M., Mills, G. B., & Liang, H. (2020) · Genome biology · doi:10.1186/s13059-020-01954-z · Cited by 55
Integrating molecular diagnostics into anticancer drug discovery
Peták, I., Schwab, R. E., Őrfi, L., Kopper, L., & Kéri, G. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3135 · Cited by 58
Practicing Pathology in the Era of Big Data and Personalized Medicine
Gu, J., & Taylor, C. R. (2013) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000022 · Cited by 58
Identifying the Ubiquitin Ligase Complex That Regulates the NF1 Tumor Suppressor and Ras
Hollstein, P. E., & Cichowski, K. M. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0146 · Cited by 60
Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Heinzle, C. F., Erdem, Z., Paur, J., Grasl‐Kraupp, B., Holzmann, K., Grusch, M., Berger, W., & Marian, B. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990594 · Cited by 56
The Hypoxic Tumor Microenvironment: Driving the Tumorigenesis of Non-Small-Cell Lung Cancer
Foster, J. G., Wong, S. C. K., & Sharp, T. V. (2014) · Future Oncology · doi:10.2217/fon.14.201 · Cited by 61
HLungDB: an integrated database of human lung cancer research
Wang, L., Xiong, Y., Sun, Y., Fang, Z., Li, L., Ji, H., & Shi, T. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp945 · Cited by 60
Genome analyses identify the genetic modification of lung cancer subtypes
Zhang, Y., Wang, D. C., Shi, L., Zhu, B., Min, Z., & Jin, J. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.11.005 · Cited by 58
Dong, C., Guo, Y., Yang, H., He, Z., Liu, X., & Wang, K. (2016) · Genome Medicine · doi:10.1186/s13073-016-0390-0 · Cited by 55
Mutation of the PTCH1 gene predicts recurrence of breast cancer
Wang, C., Chang, Y.-C., Kuo, Y., Lee, K., Chen, P., Cheung, C. H. A., Chang, C., Phan, N. N., Shen, M., & Hsu, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-52617-4 · Cited by 58
Bryant, C. M., Albertus, D. L., Kim, S., Chen, G., Brambilla, C., Guedj, M., Arima, C., Travis, W. D., Yatabe, Y., Takahashi, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011712 · Cited by 55
Self-citationGenes and Pathology of Non-Small Cell Lung Carcinoma
Sakashita, S., Sakashita, M., & Tsao, M. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.008 · Cited by 56
The ubiquitin system: orchestrating cellular signals in non-small-cell lung cancer
Fan, Q., Wang, Q., Cai, R., Yuan, H., & Xu, M. (2020) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-019-0193-6 · Cited by 58
Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors
Bhatt, V. D., Lan, T., Wang, W., Kong, J., Lopes, E. C., Wang, J., Khayati, K., Raju, A., Rangel, M., Lopez, E., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05592-8 · Cited by 61
Imaging Primary Lung Cancers in Mice to Study Radiation Biology
Kirsch, D. G., Grimm, J., Guimarães, A. R., Wojtkiewicz, G. R., Perez, B. A., Santiago, P. M., Anthony, N. K., Forbes, T., Doppke, K. P., Weissleder, R., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.11.038 · Cited by 58
Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma
Ren, S., Kuang, P., Zheng, L.-M., Su, C., Li, J., Li, B., Chen, X., Wang, Y., KimCurran, V., Liu, L., et al. (2012) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-012-9384-8 · Cited by 57
YEATS4 Is a Novel Oncogene Amplified in Non–Small Cell Lung Cancer That Regulates the p53 Pathway
Pikor, L. A., Lockwood, W. W., Thu, K. L., Vucic, E. A., Chari, R., Gazdar, A. F., Lam, S., & Lam, W. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1897 · Cited by 44
Wang, L., He, Y., Liu, W., Bai, S., Xiao, L., Zhang, J., Dhanasekaran, S. M., Wang, Z., Sundaram, S. K., Balbin, O. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7203 · Cited by 57
Self-citationTargeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma
Gilbert‐Ross, M., Konen, J. M., Koo, J., Shupe, J. A., Robinson, B. S., Wiles, W. G., Huang, C., Martin, W. D., Behera, M., Smith, G. H., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.90487 · Cited by 57
Wiesweg, M., Kasper, S., Worm, K., Herold, T., Reis, H., Sara, L., Metzenmacher, M., Abendroth, A., Darwiche, K., Aigner, C., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0634-0 · Cited by 55
LOTUS: A single- and multitask machine learning algorithm for the prediction of cancer driver genes
Collier, O., Stoven, V., & Vert, J. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007381 · Cited by 56
Identification of relevant genetic alterations in cancer using topological data analysis
Rabadán, R., Mohamedi, Y., Rubin, U., Chu, T., Alghalith, A. N., Elliott, O., Arnes, L., Cal, S., Obaya, Á. J., Levine, A. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17659-7 · Cited by 56
Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer
Pacini, L., Jenks, A. D., Lima, N. C., & Huang, P. H. (2021) · Cells · doi:10.3390/cells10051154 · Cited by 58
LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy
Ibrahim, R., Saleh, K., Chahine, C., Khoury, R., Khalife, N., & Cesne, A. L. (2023) · Biomedicines · doi:10.3390/biomedicines11071878 · Cited by 60
Wang, Y., Tu, P., Lin, K., Lin, S., Ko, J., & Jou, Y. (2011) · Neoplasia · doi:10.1593/neo.11222 · Cited by 56
Inhibitors of the anaplastic lymphoma kinase
Mologni, L. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.690031 · Cited by 58
Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms
Hollmén, M., Määttä, J. A., Bald, L. N., Sliwkowski, M. X., & Elenius, K. (2009) · Oncogene · doi:10.1038/onc.2008.481 · Cited by 56
Stachnik, A., Yuen, T., Iqbal, J. Z., Sgobba, M., Gupta, Y. K., Lü, P., Colaianni, G., Ji, Y., Zhu, L.-L., Kim, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421422111 · Cited by 56
Wnt signaling pathway: Implications for therapy in lung cancer and bone metastasis
Xi, Y., & Chen, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.010 · Cited by 56
Racial Diversity of Actionable Mutations in Non–Small Cell Lung Cancer
Bollig-Fischer, A. B., Chen, W., Gadgeel, S. M., Wenzlaff, A. S., Coté, M. L., Schwartz, A. G., & Bepler, G. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000420 · Cited by 56
Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer
Cron, K. R., Zhu, K., Kushwaha, D. S., Hsieh, G., Merzon, D., Rameseder, J., Chen, C. C., D’Andrea, A. D., & Kozono, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073710 · Cited by 61
Mechanisms of Base Substitution Mutagenesis in Cancer Genomes
Bacolla, A., Cooper, D. N., & Vásquez, K. M. (2014) · Genes · doi:10.3390/genes5010108 · Cited by 55
Metadata
- Authors
- Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., Fulton, L., Fulton, R. S., Zhang, Q., Wendl, M. C., Lawrence, M. S., Larson, D. E., Chen, K., Dooling, D. J., Sabo, A., Hawes, A. C., Shen, H., Jhangiani, S. N., Lewis, L. R., Hall, O., Zhu, Y., Mathew, T., Ren, Y., Yao, J., Scherer, S. E., Clerc, K., Metcalf, G. A., Ng, B., Milosavljevic, A., Gonzalez-Garay, M. L., Osborne, J. R., Meyer, R., Shi, X., Tang, Y., Koboldt, D. C., Lin, L., Abbott, R., Miner, T. L., Pohl, C., Fewell, G., Haipek, C., Schmidt, H., Dunford-Shore, B. H., Kraja, A., Crosby, S. D., Sawyer, C. S., Vickery, T., Sander, S., Robinson, J., Winckler, W., Baldwin, J., Chirieac, L. R., Dutt, A., Fennell, T., Hanna, M., Johnson, B. E., Onofrio, R. C., Thomas, R. K., Tonon, G., Weir, B. A., Zhao, X., Ziaugra, L., Zody, M. C., Giordano, T., Orringer, M. B., Roth, J. A., Spitz, M. R., Wistuba, I. I., Ozenberger, B., Good, P. J., Chang, A. C., Beer, D. G., Watson, M. A., Ladanyi, M., Broderick, S., Yoshizawa, A., Travis, W. D., Pao, W., Province, M. A., Weinstock, G. M., Varmus, H. E., Gabriel, S. B., Lander, E. S., Gibbs, R. A., Meyerson, M., & Wilson, R. K.
- Affiliations
- Washington University in St. Louis (US)
- Broad Institute (US)
- Baylor College of Medicine (US)
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Max Planck Society (DE)
- University of Michigan (US)
- The University of Texas MD Anderson Cancer Center (US)
- National Institutes of Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Meyerson, Matthew
- Wilson, Richard K.
- ORCID
- Ding, Li
- Getz, Gad
- Wheeler, David A.
- Mardis, Elaine R.
- McLellan, Michael D.
- Cibulskis, Kristian
- Greulich, Heidi
- Muzny, Donna M.
- Morgan, Margaret B.
- Fulton, Lucinda
- Fulton, Robert S.
- Wendl, Michael C.
- Lawrence, Michael S.
- Larson, David E.
- Chen, Ken
- Sabo, Aniko
- Shen, Hua
- Jhangiani, Shalini N.
- Zhu, Yiming
- Ren, Yanru
- Yao, Jiqiang
- Scherer, Steven E.
- Metcalf, Ginger A.
- Ng, Brian
- Milosavljevic, Aleksandar
- Tang, Yuzhu
- Koboldt, Daniel C.
- Lin, Ling
- Pohl, Craig
- Crosby, Seth D.
- Vickery, Tammi
- Winckler, Wendy
- Chirieac, Lucian R.
- Dutt, Amit
- Fennell, Tim
- Johnson, Bruce E.
- Thomas, Roman K.
- Tonon, Giovanni
- Zody, Michael C.
- Giordano, Thomas
- Roth, Jack A.
- Wistuba, Ignacio I.
- Ozenberger, Bradley
- Chang, Andrew C.
- Beer, David G.
- Watson, Mark A.
- Ladanyi, Marc
- Broderick, Stephen
- Yoshizawa, Akihiko
- Travis, William D.
- Pao, William
- Province, Michael A.
- Weinstock, George M.
- Varmus, Harold E.
- Gabriel, Stacey B.
- Lander, Eric S.
- Gibbs, Richard A.
- Meyerson, Matthew
- Wilson, Richard K.
- Venue
- Nature
- Published
- 2008-10
- Volume
- 455
- Issue
- 7216
- Pages
- 1069-1075
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2694412
- OpenAlex
- W2163798887
- Cited by
- 2,681
- References
- 54
- Citations by year
- 2026: 21 · 2025: 48 · 2024: 53 · 2023: 122 · 2022: 124 · 2021: 149 · 2020: 147 · 2019: 145 · 2018: 121 · 2017: 141 · 2016: 158 · 2015: 206 · 2014: 254 · 2013: 213 · 2012: 227
- FWCI
- 167.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Broad Institute
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (U19CA084953, P50CA070907, R01CA154365)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, carcinogenesis, tyrosine kinase, EphA3, Eph receptors, KDR, NTRK, tumor suppressor, neurofibromatosis type 1, APC, RB1, ATM, PTPRD, LRP1B, smoking, DNA repair deficiency, signaling pathways, molecular targets, mutational landscape
- MeSH terms
- Adenocarcinoma, Bronchiolo-Alveolar, Female, Humans, Lung Neoplasms, Male, Mutation, Proto-Oncogenes, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Gene Dosage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
